Frontlight ResearchEarly access
Taking people in United StatesNo phase
Early Feasibility Study (EFS) of the Nyra Cardiac Leaflet Enhancer (CARLEN) System
Key facts
- Who runs it
- Nyra Medical, Inc.
- Where
- Ann Arbor, Cincinnati, and Sacramento, United StatesSee the 3 sites
- Trial code
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 2 Jul 2026
- Expected to end
- Dec 2032
- Type of study
- Interventional
- Treatments tested
- CARLEN System
- Record updated
- 28 July 2026
Who can take part
- Age
- 21 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Age > 21 years at time of enrollment
- Patient has provided informed consent, is willing and capable of participating in all testing, and agrees to return for all required post-procedure follow-up visits
- Moderate-to-severe or severe (MR ≥ 3+) functional (secondary) mitral valve regurgitation
- Symptomatic with mitral regurgitation (NYHA Class II, III, or ambulatory IV) despite maximally-tolerated guideline-directed medical therapy (GDMT) as determined by the local multidisciplinary Heart Team
- Patient is suitable for transcatheter mitral valve repair as determined by the local multidisciplinary Heart Team and confirmed by the Eligibility Committee
Who cannot take part
- Women who are pregnant, lactating, or planning to become pregnant during the clinical study. Women of child-bearing potential must have negative pregnancy test result within 2 weeks prior to the procedure
- Known hypersensitivity or contraindications to necessary and routine medications including contrast compounds or components used in the CARLEN System that cannot be successfully pre-medicated, including nitinol, an alloy of nickel and titanium
- Aortic valve disease requiring intervention or intervention
- Severe pulmonary hypertension
- Presence of significant congenital heart disease
- Planned or scheduled cardiac surgery within next 12 months
- Evidence of intracardiac mass, vegetation, or inflammatory or infectious valve disease
- Left Ventricular Ejection Fraction (LVEF) < 20%
- Estimated life expectancy of less than 12 months
- Left ventricular end diastolic diameter (LVEDD) > 75 mm
- Acute hemodynamic decompensation
- Contraindicated for transesophageal echo (TEE)
- Presence of other anatomical characteristics and/or significant comorbidities that in the judgement of the Investigator or Eligibility Committee precludes the subject from participation
- Severe or greater tricuspid regurgitation
- Severe right ventricular dysfunction
- Endocarditis within last 90 days
Where in United States
- University of MichiganAnn Arbor, United StatesContact: Jennifer Mischke, VP of Regulatory and ClinicalTaking people
- The Christ HospitalCincinnati, United StatesContact: Jennifer Mischke, VP of Regulatory and ClinicalTaking people
- University of California - DavisSacramento, United StatesContact: Jennifer Mischke, VP of Regulatory and ClinicalTaking people
About the trial
What the trial wants to find out
Safety and performance evaluation of the CARLEN System in patients with functional mitral valve regurgitation.
The group in the trial
- CARLEN SystemTreatment being tested
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- ENHANCE EFS: Early Feasibility Study (EFS) of the Nyra Cardiac Leaflet Enhancer (CARLEN) System
- Record updated
- 28 July 2026